Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $6 | $11 | $7 |
| G&A Expenses | $5 | $6 | $9 | $5 |
| SG&A Expenses | $5 | $6 | $9 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $7 | $1 |
| Operating Expenses | $12 | $11 | $28 | $12 |
| Operating Income | -$12 | -$11 | -$28 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$12 | -$11 | -$27 | -$12 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$12 | -$11 | -$27 | -$11 |
| % Margin | – | – | – | – |
| EPS | -96.75 | -212 | -42.5 | -373 |
| % Growth | 54.4% | -398.8% | 88.6% | – |
| EPS Diluted | -96.75 | -212 | -42.5 | -373 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$12 | -$11 | -$19 | -$11 |
| % Margin | – | – | – | – |